

## Vizimpro (dacomitinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			
MALE FEMALE HEIGHT (IN/CM): WE  IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DI  FOLLOWING LINK: HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/CC	ISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE		
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):			
PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL DISPENSING INFORMATION	V		
MEDICATION NAME:			
DOSE/STRENGTH: FREQUENCY:	LENGTH OF QUANTITY: THERAPY/REFILLS:		
□ NEW THERAPY     □ RENEWAL     IF RENEWAL: DATE THERAPY INITIATED:       DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





## Vizimpro (dacomitinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
□ Non-Small Cell Lung Cancer (NSCLC) □ Other diagnosis:	ICD-10 Code(s):		
PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A	
-	oth Factor Receptor (EGFR) exon 19 dele nit lab documentation of mutations.	etion or exon 21 L858R substitution	
Is the patient completely ambulatory? □ Yes □ No			
Does the patient have brain or leptomeningeal metastases? ☐ Yes ☐ No			
Does patient have newly diagnosed unresectable metastatic disease? ☐ Yes ☐ No If yes to being newly diagnosed with unresectable metastatic disease, has the patient been previously treated for metastatic disease? ☐ Yes ☐ No			
Does the patient have recurrent diseased of the patient having recurrent disease prior systemic therapy? ☐ Yes ☐ No	ease, has the patient had a disease-free	interval of at least 12months since	
Are there any other comments, diagnorphysician feels is important to this rev	oses, symptoms, medications tried or fa iew?	iled, and/or any other information the	
Please note: Not all drugs/diagnosis are information is received.	e covered on all plans. This request may	be denied unless all required	
the Health Plan, insurer, Medical Group	n provided is true and accurate to the be o or its designees may perform a routine uracy of the information reported on thi	audit and request the medical	
Prescriber Signature or Electronic I.D.	Verification:	Date:	
you are not the intended recipient, you are here	ompanying this transmission contain confidential by notified that any disclosure, copying, distribution in error, please no	tion, or action taken in reliance on the contents	

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.